Drug intelligence / Profile preview

desloratadine + betamethasone

Development stage
Unknown
Lead developer
Laboratorios Silanes
Modality
Small Molecules
Administration
Oral, Topical
01

Overview

**Desloratadine + betamethasone** is an oral fixed-dose anti-allergic combination of desloratadine, a second-generation peripheral histamine H1-receptor inverse agonist, and betamethasone, a synthetic glucocorticoid receptor agonist with anti-inflammatory and immunosuppressive activity. It is marketed in several countries as products including Frenaler Cort and Oradus Beta for severe allergic and inflammatory conditions, including allergic rhinitis, urticaria, angioedema, atopic dermatitis, allergic contact dermatitis, allergic conjunctivitis, and food- or medicine-associated allergic reactions. Available products include film-coated tablets and oral liquid formulations; tablet products commonly contain desloratadine 5 mg plus betamethasone 0.6 mg. ([pharmaline.com.lb](https://www.pharmaline.com.lb/pharmaline/english/products/oradus-beta))

Brand names
Deline CortDesaler CortDeslamed ForteFrenaler CortHexaler CortOradus Beta
Other names
betamethasone + desloratadinedesloratadine + betamethasonedesloratadine/betamethasone
02

Targets

GR (Glucocorticoid receptor)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on desloratadine + betamethasone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on desloratadine + betamethasone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call